Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
तुलना करने के लिए मीट्रिक्स | ALDVI | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधALDVIपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −2.3x | −1.2x | −0.6x | |
PEG अनुपात | −0.08 | 0.00 | 0.00 | |
क़ीमत/बुक | −1.2x | 1.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 6.1x | 1.9x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 208.8% | 38.9% | 49.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 16.3% | 7.8% | अनलॉक करें |